It is estimated that HSDD affects approximately 10% of adult women, with symptoms that include lack or loss of motivation to participate in sexual activity, lack or loss of sexual desire, or the lack or loss of ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress1. "HSDD and the multi-factorial issues that impact women's sexual health are well-established. HSDD's impact is both real and significant, and therefore deserves to be acknowledged, addressed and discussed by women and their healthcare provider," said Dr. Vivien Brown MDCM, CCFP, FCFP, NCMP, Assistant Professor at the University of Toronto and VP North America, Medical Women's International Association. "The availability of Addyi empowers women to take control of the discussion about HSDD and their overall sexual health, to consider an evidence-based option that is finally available for HSDD, and to make a decision as to what is the appropriate approach to improve each woman's sexual health and quality of life."